TDSPharm Co

TDSPharm Co Net Margin

The Net Profit Margin of TDSPharm Co (464280.KQ) as of Oct 25, 2026 is 15.48 %. In the previous year, Net Profit Margin was 13.51 % — a change of 14.55% (higher).

Net Margin

15.48 %

YoY

14.55%

Last updated:

Net Profit Margin of TDSPharm Co is 2025 15.48 % . Net Profit Margin of TDSPharm Co was 2024 13.51 % . It decreases by 14.55% higher compared to the previous year.

For TDSPharm Co, the net margin of 15.6% is up versus 10.5% a few years ago.

The TDSPharm Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2021
10.41 KRW
Jan 1, 2022
13.50 KRW
Jan 1, 2023
15.60 KRW
Jan 1, 2024
13.51 KRW
Jan 1, 2025
15.48 KRW
The TDSPharm Co Net Margin history
YEARNet MarginYoY
15.48 %+14.55%
13.51 %-13.40%
15.60 %+15.52%
13.50 %+29.75%
10.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

Net Profit Margin of TDSPharm Co is 15.48 % in 2025.

Net Profit Margin of TDSPharm Co changed from 13.51 % to 15.48 %, representing a 14.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's TDSPharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — TDSPharm Co

All Key Metrics — TDSPharm Co